Browse by author
Lookup NU author(s): Dr Bridget Griffiths
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© The Author(s) 2026. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. Objectives: In England, there is a ‘hard stop’ to weekly tocilizumab (qwTCZ) therapy for GCA; this is currently 12 months but was extended during the COVID-19 pandemic subject to certain criteria for GCA relapse risk. Taking advantage of variation in practice, we aimed to compare outcomes of GCA patients who tapered-TCZ vs those who stopped abruptly (non-taper patients). Methods: Secondary analysis of an English multicentre service evaluation of relapse after stopping qwTCZ for GCA. Time to relapse was compared between taper and non-taper patients. We examined outcomes according to whether they had been ‘adequate responders’ during qwTCZ therapy, defined as those in remission and on ≤5 mg prednisolone at qwTCZ cessation, without relapse whilst taking qwTCZ. Results: We analysed 336 patients from 40 centres. Time to relapse after qwTCZ cessation was significantly longer in adequate responders than non-adequate responders (P ¼ 0.0004). 17.0% (57/336) patients tapered to fortnightly TCZ after qwTCZ cessation, for a median of 6 (IQR 2–13) months. For adequate responders, time to relapse whilst taking tapered-dose TCZ was significantly longer compared with those in the non-taper group (P ¼ 0.0231) based on a relatively small number of flares. There was no difference between the taper and non-tapered groups after tapered-TCZ was stopped (P ¼ 0.8346). In contrast, time to relapse for non-adequate responders was similar in taper patients compared with non-taper patients (P ¼ 0.4892). Conclusion: Tapering TCZ after qwTCZ cessation delayed relapse only during the tapering period, but only in adequate responders to qwTCZ. No lasting benefit was seen after tapering ended.
Author(s): Quick V, Sah S, Dubey S, Mercer L, Nair JR, Coath FL, Kurshid M, Abusalameh M, Ahmed S, Alkoky H, Bukhari M, Carter S, Davidson B, Doddamani P, Ducker G, Griffiths B, Gullick N, Heaney J, Holloway A, Htut EEP, Hughes M, Irvine H, Kinder A, Lim J, Ludwig DR, Malik M, Mulhearn B, Patel R, Robson J, Saha P, Tansley S, Mackie SL, Ahmed S, Atchia I, Bluett J, Connew A, Coulson E, Crawshaw H, Davies U, De Lord D, Dulay G, Embuldeniya A, Fonseca C, Galloway J, Gubbins W, Guruparan T, Heaton R, James M, Janagan S, Johnson H, Karim A, Khalid S, Kinsey K, Koduri G, Linton S, MacPhie E, Mahto A, Mukhtyar C, Nandagudi AC, Nandi P, Osman F, Plumb S, Quinlan E, Redfern A, Regan M, Reid V, Roy D, Saeed S, Smith A, Steel L, Thomas R, Ugwoke A, Villar S, Williams E, Wood F, Xie M
Publication type: Article
Publication status: Published
Journal: Rheumatology
Year: 2026
Volume: 65
Issue: 1
Print publication date: 01/01/2026
Online publication date: 26/08/2025
Acceptance date: 02/08/2025
ISSN (print): 1462-0324
ISSN (electronic): 1462-0332
Publisher: Oxford University Press
URL: https://doi.org/10.1093/rheumatology/keaf450
DOI: 10.1093/rheumatology/keaf450
PubMed id: 40857555
Altmetrics provided by Altmetric
